
New in @TheLancetOncol : outcomes for patients with #RCC brain metastases are changing. In 1,049 patients, median OS was 20 months—up from 9.6–12 months in historical cohorts. Updated Renal GPA predicts survival from 4.8 to 51.2 months. Important message: brain metastases should not automatically exclude patients from clinical trials. Proud to contribute to this international effort led by Paul Sperduto and Minesh Mehta. thelancet.com/journals/lanon… @RifRahmanMD @SanjayAnejaMD @Luke_Pike_MD @TonyWangMD @SteveBraunstein @TugceKutukMD @Rrkotecha @DukeCancer @DukeRadOnc @MiamiCancerInst @BaptistHealthSF






